Key result
Female sex in DSP cardiomyopathy is linked to ~4-fold higher rates of heart failure progression.
Why the study?
Data on long-term outcomes and disease modifiers in desmoplakin (DSP)-related cardiomyopathy, including sex-specific differences and immune-mediated inflammatory diseases (IMIDs), were limited.
Cohort (n=22)
Yes
Desmoplakin-related cardiomyopathy is characterized by extensive myocardial fibrosis, frequent ventricular arrhythmias, and progressive heart failure, with an exploratory association showing immune-mediated inflammatory diseases occurring exclusively in women and higher rates of heart failure progression in female patients.
Answers are grounded in this paper and cite their sources.
May link immune-mediated inflammation to injury in DSP cardiomyopathy; hypothesis-generating and requires prospective validation before practice change.
Background: Desmoplakin (*DSP*)-related cardiomyopathy is a distinct arrhythmogenic cardiomyopathy with predominant left ventricular involvement, myocardial fibrosis, and recurrent myocarditis-like episodes; data on long-term outcomes and disease modifiers are limited. Aims: Our aim was to characterize clinical phenotype, myocardial injury, and long-term outcomes, focusing on sex-specific differences and immune-mediated inflammatory diseases (IMIDs). Methods: Between 2012 and 2025, we identified 14 probands with likely pathogenic/pathogenic *DSP* variants by next-generation sequencing (10 from a previously characterized nationwide 280-proband dilated cardiomyopathy cohort, 4 subsequently) and 8 relatives *via* cascade screening, yielding 22 subjects analyzed for clinical, electrocardiographic, imaging, biomarker, and follow-up data. Results: Median age at onset was 28 years (interquartile range [IQR] 18.7–40.3); 68% had non-dilated left ventricular cardiomyopathy and 86% had ventricular ectopy. Cardiac magnetic resonance (CMR) showed late gadolinium enhancement in 94% (15/16 with available CMR). High-sensitivity troponin T was elevated in 32%, with CMR inflammation in 37%. Over 145 months (IQR 61–150), heart failure (HF) progression occurred in 45%, sustained ventricular tachycardia in 31%, and biventricular involvement in 14%. IMIDs were identified in 23%, exclusively in women (46% vs. 0%; *P* = 0.019), who had more frequent HF progression (75% vs. 17%; *P* = 0.043). IMID-positive patients showed a trend toward earlier onset (19 vs. 31 years; *P* = 0.056); this was considered exploratory given confounding with female sex. Conclusions: *DSP*-related cardiomyopathy is marked by extensive fibrosis, frequent ventricular arrhythmias, and progressive HF. IMIDs were observed exclusively in women, and female sex was associated with higher HF progression; this relationship remains exploratory and requires validation in larger cohorts.
No takes yet. Share an insight, caveat, or question.
Zakrzewska‐Koperska et al. (2026) conducted a cohort in Desmoplakin (DSP)-related cardiomyopathy (n=22). Female sex and immune-mediated inflammatory diseases (IMIDs) vs. Male sex / IMID-negative patients was evaluated on Heart failure progression (p=0.043). In DSP cardiomyopathy, female sex was associated with higher rates of immune-mediated inflammatory diseases and heart failure progression.
Synapse has enriched 10 related papers. Consider them for comparative context: